Response | Overall | Group A | Group B | Â |
---|---|---|---|---|
HCV genotype | n/N (%) | n/N (%) | n/N (%) | p-value |
RVR | 102/151 (67.5) | 21/36 (58.3) | 81/115 (70.4) | 0.176 |
 1 | 50/91 (54.9) | 9/22 (40.9) | 41/69 (59.4) | 0.129 |
 Non-1 | 52/60 (86.7) | 12/14 (85.7) | 40/46 (87) | 0.9.5 |
cEVR | 140/154 (90.9) | 30/37 (81.1) | 110/117 (94) | 0.017 |
 1 | 77/91 (84.6) | 15/22 (68.2) | 62/69 (89.9) | 0.014 |
 Non-1 | 63/63 (100) | 15/15 (100) | 48/48 (100) | – |
ETR | 148/168 (88.1) | 36/42 (85.7) | 112/126 (88.9) | 0.582 |
 1 | 84/100 (84) | 21/25 (84) | 63/75 (84) | 1 |
 Non-1 | 64/68 (94.1) | 15/17 (88.2) | 49/51 (96.1) | 0.234 |
SVR | 98/168 (58.3) | 19/42 (45.2) | 79/126 (69.7) | 0.047 |
 1 | 46/100 (46) | 6/25 (24)* | 40/75 (53.3)** | 0.011 |
 Non-1 | 53/68 (76.5) | 13/17 (76.5)* | 39/51 (76.5)** | 1.0 |
SVR (with RVR) | 77/102 (75.5) | 14/21 (66.7) | 63/81 (77.8) | 0.291 |
 1 | 35/50 (70) | 4/9 (44.4) | 31/41 (75.6) | 0.065 |
 Non-1 | 42/52 (80.8) | 10/12 (83.3) | 32/40 (80) | 0.797 |
Relapse | 50/148 (33.8) | 17/36 (47.2) | 33/112 (29.5) | 0.05 |
 1 | 38/84 (45.2)# | 15/21 (71.4) | 23/63 (36.5) | 0.005 |
 Non-1 | 12/64 (18.8)# | 2/15 (13.3) | 10/49 (20.4) | 0.539 |
Discontinuation | 13/168 (7.7) | 6/42 (14.3) | 7/126 (5.6) | 0.067 |
 1 | 8/100 (8) | 3/25 (12) | 5/75 (6.7) | 0.395 |
 Non-1 | 5/68 (7.4) | 3/17 (17.6) | 2/51 (3.9) | 0.06 |